Literature DB >> 21270149

N1L is an ectromelia virus virulence factor and essential for in vivo spread upon respiratory infection.

Meike S Gratz1, Yasemin Suezer, Melanie Kremer, Asisa Volz, Monir Majzoub, Kay-Martin Hanschmann, Ulrich Kalinke, Astrid Schwantes, Gerd Sutter.   

Abstract

The emergence of zoonotic orthopoxvirus infections and the threat of possible intentional release of pathogenic orthopoxviruses have stimulated renewed interest in understanding orthopoxvirus infections and the resulting diseases. Ectromelia virus (ECTV), the causative agent of mousepox, offers an excellent model system to study an orthopoxvirus infection in its natural host. Here, we investigated the role of the vaccinia virus ortholog N1L in ECTV infection. Respiratory infection of mice with an N1L deletion mutant virus (ECTVΔN1L) demonstrated profound attenuation of the mutant virus, confirming N1 as an orthopoxvirus virulence factor. Upon analysis of virus dissemination in vivo, we observed a striking deficiency of ECTVΔN1L spreading from the lungs to the livers or spleens of infected mice. Investigating the immunological mechanism controlling ECTVΔN1L infection, we found the attenuated phenotype to be unaltered in mice deficient in Toll-like receptor (TLR) or RIG-I-like RNA helicase (RLH) signaling as well as in those missing the type I interferon receptor or lacking B cells. However, in RAG-1(-/-) mice lacking mature B and T cells, ECTVΔN1L regained virulence, as shown by increasing morbidity and virus spread to the liver and spleen. Moreover, T cell depletion experiments revealed that ECTVΔN1L attenuation was reversed only by removing both CD4(+) and CD8(+) T cells, so the presence of either cell subset was still sufficient to control the infection. Thus, the orthopoxvirus virulence factor N1 may allow efficient ECTV infection in mice by interfering with host T cell function.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21270149      PMCID: PMC3067874          DOI: 10.1128/JVI.01191-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  72 in total

Review 1.  Construction and isolation of recombinant vaccinia virus using genetic markers.

Authors:  María M Lorenzo; Inmaculada Galindo; Rafael Blasco
Journal:  Methods Mol Biol       Date:  2004

Review 2.  Growing poxviruses and determining virus titer.

Authors:  Girish J Kotwal; Melissa-Rose Abrahams
Journal:  Methods Mol Biol       Date:  2004

3.  Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension.

Authors:  R M Horton; H D Hunt; S N Ho; J K Pullen; L R Pease
Journal:  Gene       Date:  1989-04-15       Impact factor: 3.688

4.  Vaccinia pneumonia in mice. A light and electron microscopic and viral assay study.

Authors:  M Montasir; E R Rabin; C A Phillips
Journal:  Am J Pathol       Date:  1966-05       Impact factor: 4.307

5.  A dominant selectable marker for the construction of recombinant poxviruses.

Authors:  D B Boyle; B E Coupar
Journal:  Gene       Date:  1988-05-15       Impact factor: 3.688

Review 6.  Human monkeypox: an emerging zoonosis.

Authors:  Daniel B Di Giulio; Paul B Eckburg
Journal:  Lancet Infect Dis       Date:  2004-01       Impact factor: 25.071

7.  Induction of potent humoral and cell-mediated immune responses by attenuated vaccinia virus vectors with deleted serpin genes.

Authors:  Fatema A Legrand; Paulo H Verardi; Leslie A Jones; Kenneth S Chan; Yue Peng; Tilahun D Yilma
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

8.  Poxvirus genomes: a phylogenetic analysis.

Authors:  Caroline Gubser; Stéphane Hué; Paul Kellam; Geoffrey L Smith
Journal:  J Gen Virol       Date:  2004-01       Impact factor: 3.891

9.  Vaccinia virus encodes a previously uncharacterized mitochondrial-associated inhibitor of apoptosis.

Authors:  Shawn T Wasilenko; Tara L Stewart; Adrienne F A Meyers; Michele Barry
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-10       Impact factor: 11.205

10.  Poxvirus protein N1L targets the I-kappaB kinase complex, inhibits signaling to NF-kappaB by the tumor necrosis factor superfamily of receptors, and inhibits NF-kappaB and IRF3 signaling by toll-like receptors.

Authors:  Gary DiPerna; Julianne Stack; Andrew G Bowie; Annemarie Boyd; Girish Kotwal; Zhouning Zhang; Sheila Arvikar; Eicke Latz; Katherine A Fitzgerald; William L Marshall
Journal:  J Biol Chem       Date:  2004-06-23       Impact factor: 5.157

View more
  8 in total

1.  The vaccinia virus-encoded Bcl-2 homologues do not act as direct Bax inhibitors.

Authors:  Antonio Postigo; Michael Way
Journal:  J Virol       Date:  2011-10-19       Impact factor: 5.103

Review 2.  Poxviruses and the evolution of host range and virulence.

Authors:  Sherry L Haller; Chen Peng; Grant McFadden; Stefan Rothenburg
Journal:  Infect Genet Evol       Date:  2013-10-24       Impact factor: 3.342

Review 3.  The current status and future directions of myxoma virus, a master in immune evasion.

Authors:  Bart Spiesschaert; Grant McFadden; Katleen Hermans; Hans Nauwynck; Gerlinde R Van de Walle
Journal:  Vet Res       Date:  2011-06-09       Impact factor: 3.683

4.  Critical role of perforin-dependent CD8+ T cell immunity for rapid protective vaccination in a murine model for human smallpox.

Authors:  Melanie Kremer; Yasemin Suezer; Asisa Volz; Theresa Frenz; Monir Majzoub; Kay-Martin Hanschmann; Michael H Lehmann; Ulrich Kalinke; Gerd Sutter
Journal:  PLoS Pathog       Date:  2012-03-01       Impact factor: 6.823

5.  Inhibition of apoptosis and NF-κB activation by vaccinia protein N1 occur via distinct binding surfaces and make different contributions to virulence.

Authors:  Carlos Maluquer de Motes; Samantha Cooray; Hongwei Ren; Gabriel M F Almeida; Kieran McGourty; Mohammad W Bahar; David I Stuart; Jonathan M Grimes; Stephen C Graham; Geoffrey L Smith
Journal:  PLoS Pathog       Date:  2011-12-15       Impact factor: 6.823

6.  Enhancement of CD8(+) T-cell memory by removal of a vaccinia virus nuclear factor-κB inhibitor.

Authors:  Hongwei Ren; Brian J Ferguson; Carlos Maluquer de Motes; Rebecca P Sumner; Laura E R Harman; Geoffrey L Smith
Journal:  Immunology       Date:  2015-05       Impact factor: 7.397

7.  A marker-free system for highly efficient construction of vaccinia virus vectors using CRISPR Cas9.

Authors:  Ming Yuan; Xuefei Gao; Louisa S Chard; Zarah Ali; Jahangir Ahmed; Yunqing Li; Pentao Liu; Nick R Lemoine; Yaohe Wang
Journal:  Mol Ther Methods Clin Dev       Date:  2015-09-16       Impact factor: 6.698

8.  A new oncolytic V accinia virus augments antitumor immune responses to prevent tumor recurrence and metastasis after surgery.

Authors:  Jahangir Ahmed; Louisa S Chard; Ming Yuan; Jiwei Wang; Anwen Howells; Yuenan Li; Haoze Li; Zhongxian Zhang; Shuangshuang Lu; Dongling Gao; Pengju Wang; Yongchao Chu; Chadwan Al Yaghchi; Joel Schwartz; Ghassan Alusi; Nicholas Lemoine; Yaohe Wang
Journal:  J Immunother Cancer       Date:  2020-03       Impact factor: 13.751

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.